Table 5—

UAE, urinary l-FABP levels, and total cholesterol before and after treatment in diabetic patients with microalbuminuria (group B)

Before treatment6 months12 months
UAE (μg/min)
    Pitavastatin110 ± 7488 ± 60*†58 ± 32‡§
    Nonpitavastatin104 ± 68110 ± 72118 ± 74
l-FABP (μg/g creatinine)
    Pitavastatin18.6 ± 12.512.2 ± 8.8*†8.8 ± 6.4‡§
    Nonpitavastatin20.6 ± 14.522.0 ± 16.024.0 ± 18.0
Total cholesterol (mg/dl)
    Pitavastatin180 ± 28172 ± 24170 ± 26
    Nonpitavastatin185 ± 34180 ± 28184 ± 30

  • Data are means ± SD. Versus before treatment:

  • *

    ↵* P < 0.05 and

  • ‡

    ↵‡ P < 0.01. Versus nonpitavastatin treatment:

  • †

    ↵† P < 0.05 and

  • §

    ↵§ P < 0.01.